Michael Serzan is a hematology/oncology fellow at the Georgetown Lombardi Comprehensive Cancer Center in Washington, DC. Dr Serzan’s vision is to optimize outcomes for all patients treated with immune-based therapies. His clinical interests are in the treatment of patients with advanced genitourinary and cutaneous malignancies. His research focus is in early phase clinical trials and biomarkers of immune-mediated adverse events. He is the lead investigator on a retrospective immuno-oncology database and a clinical trial for patients with advanced kidney cancer. He has participated in the AACR Vail Clinical Trial Workshop and the FDA Oncology Educational Fellowship.